MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE
Clinical trials for MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Allergy pill shows promise for MS repair in small trial
Disease control Recruiting nowThis study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans …
Matched conditions: MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental CAR-T therapy takes on progressive MS
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not responding to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy certain immune cells …
Matched conditions: MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Smartphone app and biobank join forces to decode MS progression
Knowledge-focused Recruiting nowThis study is collecting health data, smartphone app measurements, and biological samples from 100 people with multiple sclerosis. Researchers aim to find new biomarkers and digital tools to better understand how MS progresses and when it changes form. The goal is to improve moni…
Matched conditions: MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC